Findings from Chinese Academy of Sciences Yields New Findings on Small Cell Lung Cancer (Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer)
By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Lung Diseases and Conditions have been published. According to news reporting from Beijing, People's Republic of China, by NewsRx journalists, research stated, "Despite progress, combination therapy of different functional drugs to increase the efficiency of anticancer treatment still remains challenges. An amphiphilic methoxy poly(ethylene glycol)-b-poly(L-glutamic acid)-b-poly(L-lysine) triblock copolymer decorated with deoxycholate (mPEsG-b-PLG-b-PLL/DOCA) was synthesized and developed as a nanovehicle for the co-delivery of anticancer drugs: doxorubicin (DOX) and paclitaxel (PTX)."
The news correspondents obtained a quote from the research from the Chinese Academy of Sciences, "The amphiphilic copolymer spontaneously self-assembled into micellar-type nanoparticles in aqueous solutions and the blank nanoparticles possessed excellent stability. Three different domains of the copolymer performed distinct functions: PEG outer corona provided prolonged circulation, middle biodegradable and hydrophilic PLG shell was designed for DOX loading through electrostatic interactions, and hydrophobic deoxycholate modified PLL served as the container for FIX. In vitro cytotoxicity assays against A549 human lung adenocarcinoma cell line demonstrated that the DOX + PTX co-delivered nanoparticles (Co-NPs) exhibited synergistic effect in inducing cancer cell apoptosis. Ex vivo DOX fluorescence imaging revealed that Co-NPs had highly efficient targeting and accumulation at the implanted site of A549 xenograft tumor in vivo."
According to the news reporters, the research concluded: "Co-NPs exhibited significantly higher antitumor efficiency in reducing tumor size compared to free drug combination or single drug-loaded nanoparticles, while no obvious side effects were observed during the treatment, indicating this co-delivery system with different functional antitumor drugs provides the clinical potential in cancer therapy."
For more information on this research see: Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials, 2014;35(23):6118-6129. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news journalists report that additional information may be obtained by contacting S.X. Lv, Univ Chinese Academy Sci, Beijing 100039, People's Republic of China. Additional authors for this research include Z.H. Tang, M.Q. Li, J. Lin, W.T. Song, H.Y. Liu, Y.B. Huang, Y.Y. Zhang and X.S. Chen (see also Lung Diseases and Conditions).
Keywords for this news article include: Asia, Antibiotics - Antineoplastics, Pharmaceuticals, Drugs, Beijing, Taxoids, Therapy, Oncology, Terpenes, Paclitaxel, Hydrocarbons, Nanoparticle, Cycloparaffins, Lung Neoplasms, Nanotechnology, Organic Chemicals, Mitotic Inhibitors, Emerging Technologies, Small Cell Lung Cancer, Doxorubicin Hydrochloride
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC